Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 5, Number 1—February 1999

Synopsis

Using Monoclonal Antibodies to Prevent Mucosal Transmission of Epidemic Infectious Diseases

Larry Zeitlin*, Richard A. Cone*†, and Kevin J. Whaley*†Comments to Author 
Author affiliations: *ReProtect, LLC, Baltimore, Maryland, USA; †The Johns Hopkins University, Baltimore, Maryland, USA

Main Article

Table 2

Examples of highly effective topical passive immunization of mucosa

Pathogen Speciesa Routeb Anti-bodyc Prevention Ref.
Viruses
Herpes simplex mou v m 100% (64, 65)
r m 100% (66)
Influenza fer o p 100% (67)
mou n p > 4d (68)
Rotavirus hum o p 100% (69, 70)
Respiratory syncytial mon n m 3-4d (71)
Bacteria
Chlamydia trachomatis mou v m 90% (72)
Clostridium difficule ham o p 100% (73)
Escherichia coli hum o p 100% (74)
Porphyromonas gingivalis hum o m 100% (75)
Shigella flexneri hum o p 100% (76)
Staphylococcus aureus mou n p 3-4e (77)
Streptococcus mutans hum o m 100% (78)
Vibrio cholerae mou o m 100% (79)
Fungi
Candida albicans mou v p >50f (80)
Parasites
Cryptosporidium parvum mou o m 77g (81)

aSpecies tested in: mou=mouse; fer=ferret; hum=human; mon=monkey; ham=hamster.
bDelivery route of pathogen and antibody: v=vaginal; r=rectal; o=oral; n=nasal.
cAntibody: m=monoclonal; p=polyclonal.
d log10 reduction in virus titer.
e log10 reduction in cfu.
f % reduction in cfu.
g % reduction in number of parasites.

Main Article

Top of Page

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO